Migraine in Patients Undergoing PFO Closure: Characterization of a Platelet-Associated Pathophysiological Mechanism: The LEARNER Study.
GSH, reduced glutathione
GSSG, oxidized glutathione
HS, healthy subject(s)
MHA, migraine headache with aura
MV, microvesicles
NAC, N-acetylcysteine
PFO, patent foramen ovale
PS, phosphatidylserine
ROS, reactive oxygen species
TF, tissue factor
WB, whole blood
cTTE, contrast transthoracic echocardiography
migraine with aura
oxidative stress
patent foramen ovale
platelets
tissue factor
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
09
11
2021
revised:
03
02
2022
accepted:
03
02
2022
entrez:
12
7
2022
pubmed:
13
7
2022
medline:
13
7
2022
Statut:
epublish
Résumé
The association between migraine and patent foramen ovale (PFO) has been documented. We aimed to investigate platelet activation, prothrombotic phenotype, and oxidative stress status of migraineurs with PFO on 100 mg/day aspirin, before and 6 months after PFO closure. Data show that, before PFO closure, expression of the classical platelet activation markers is comparable in patients and aspirin-treated healthy subjects. Conversely, MHA-PFO patients display an increased prothrombotic phenotype (higher tissue factor
Identifiants
pubmed: 35818509
doi: 10.1016/j.jacbts.2022.02.002
pii: S2452-302X(22)00037-7
pmc: PMC9270571
doi:
Banques de données
ClinicalTrials.gov
['NCT03521193']
Types de publication
Journal Article
Langues
eng
Pagination
525-540Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
This work was supported by a grant from Italian Ministry of Health (Ricerca Corrente 2018-19). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
J Chin Med Assoc. 2004 Jun;67(6):263-7
pubmed: 15366402
Cephalalgia. 1985 May;5 Suppl 2:87-8
pubmed: 4016945
J Thromb Haemost. 2008 Dec;6(12):2035-44
pubmed: 18983514
Life Sci. 1998;62(20):1817-24
pubmed: 9600323
Cephalalgia. 1997 Aug;17(5):580-4
pubmed: 9251872
Blood Cells Mol Dis. 2008 Mar-Apr;40(2):174-9
pubmed: 17964197
Eur Rev Med Pharmacol Sci. 2010 Oct;14(10):877-82
pubmed: 21222375
Int J Mol Sci. 2020 Jun 15;21(12):
pubmed: 32549393
J Am Coll Cardiol. 2005 Feb 15;45(4):493-5
pubmed: 15708692
J Am Coll Cardiol. 2021 Feb 16;77(6):667-676
pubmed: 33573735
Cephalalgia. 2004;24 Suppl 1:9-160
pubmed: 14979299
Am J Cardiol. 2008 Oct 1;102(7):916-20
pubmed: 18805122
Cephalalgia. 2008 May;28(5):531-40
pubmed: 18355348
Headache. 2001 Jun;41(6):609-11
pubmed: 11437906
Cephalalgia. 2005 Jul;25(7):536-41
pubmed: 15955041
Expert Rev Neurother. 2008 Sep;8(9):1331-7
pubmed: 18759545
Eur J Neurol. 2011 Oct;18(10):1233-9
pubmed: 21518147
Headache. 1987 Sep;27(8):431-4
pubmed: 3667260
Lancet. 1972 Mar 18;1(7751):618-9
pubmed: 4110317
Thromb Haemost. 2014 Jan;111(1):67-78
pubmed: 24108579
Am J Med. 2020 Apr;133(4):412-416
pubmed: 31712099
Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jun;12(6):440-3
pubmed: 20540852
Cephalalgia. 1990 Oct;10(5):213-9
pubmed: 2272090
J Clin Pathol. 1971 Apr;24(3):250-8
pubmed: 5573439
Thromb Res. 2007;119(2):217-22
pubmed: 16504253
Headache. 2016 Jan;56(1):12-35
pubmed: 26639834
Lancet. 1982 May 29;1(8283):1248
pubmed: 6123003
Catheter Cardiovasc Interv. 2011 Mar 1;77(4):570-4
pubmed: 21351231
JAMA. 1990 Oct 3;264(13):1711-3
pubmed: 2204739
Cephalalgia. 2001 Apr;21(3):167-8
pubmed: 11442549
Cephalalgia. 1985 May;5 Suppl 2:89-91
pubmed: 3160475
Neurology. 2018 Nov 27;91(22):1002-1009
pubmed: 30478066
Lancet. 1981 Oct 3;2(8249):720-3
pubmed: 6116859
Thromb Res. 2014 Jul;134(1):17-22
pubmed: 24767953